Dr. Tara C. Gangadhar on Atypical Responses with Immunotherapies in Melanoma

Video

Tara C. Mitchell, MD, assistant professor of Medicine at the Hospital of the University of Pennsylvania, Perelman School of Medicine, discusses atypical responses with immunotherapies in melanoma.

Tara C. Mitchell, MD, assistant professor of Medicine, Perelman School of Medicine at the Hospital of the University of Pennsylvania, discusses atypical responses with immunotherapies in melanoma.

Compared to cytotoxic chemotherapy, responses can sometime be delayed with immunotherapy agents, says Mitchell.

On the first response assessment after immunotherapy, the tumor may appear larger or the same size as it was before treatment. This may be because the immunotherapy can take a longer time to work, or it could be due to immunotherapy-related inflammation in the tumor. This type of inflammation can sometimes look radiographically like a larger tumor, but a subsequent response assessment will reveal good tumor shrinkage and response, says Mitchell.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD
Shruti Tiwari, MD